Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara has appointed Brian Cherry to its Board of Directors. Cherry holds a BA from Princeton University and an MBA from The Wharton School at the University of Pennsylvania.

Brian Cherry has more than 25 years of experience investing in and helping grow companies across industries such as healthcare, industrials, business services, financial services, and consumer products.

Throughout his career, he has led buyout and growth equity investments in companies with a combined enterprise value of more than $25 billion. He previously served as a Managing Partner at private equity firm Oak Hill Capital.

Cherry also has extensive board experience, serving on the boards of more than a dozen public and private companies. In addition, he has worked with the U.S. Air Force Academy Foundation and the Undergraduate Financial Aid Leadership Council at the University of Pennsylvania.

Read More:Aton Health Announces Series A Growth Investment

Dr. Nguyen added, “Brian brings complementary expertise to the Board, his experience in capital allocation and strategic acquisitions supports our focus on creating long-term shareholder value. We look forward to him joining the board and working with our management team.”

“On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “Carol has been a pillar on the Board of Directors, serving in multiple roles over the course of her tenure. We wish Carol continued success in her future endeavors.”

About Atara Biotherapeutics

Founded in 2012, Atara is a biotechnology company developing off-the-shelf T-cell therapies for patients with difficult to treat cancers and autoimmune diseases. Its therapies are designed to be readily available from inventory, allowing faster treatment delivery. Atara was the first company to receive regulatory approval for an allogeneic T-cell immunotherapy. The company’s T-cell platform supports a pipeline of therapies targeting Epstein-Barr virus (EBV which is linked to several serious diseases.

Read More:Wafra Announces Acquisition of Navitas Credit Corp